RT Journal Article
SR Electronic
T1 Evaluation of first-pass extraction fraction of [<sup>18</sup>F]labeled fluoroalkylphosphonium salts in isolated rat heart: Comparison with [<sup>13</sup>N]NH<sub>3</sub>
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 409
OP 409
VO 55
IS supplement 1
A1 Kim, Dong-Yeon
A1 Reder, Sybille
A1 Kim, Hyeon-Sik
A1 Herz, Michael
A1 Pyo, AYoung
A1 Bom, Hee-Seung
A1 Schwaiger, Markus
A1 Min, Jung-Joon
YR 2014
UL http://jnm.snmjournals.org/content/55/supplement_1/409.abstract
AB 409 Objectives Despite substantial advances in the diagnosis of cardiovascular diseases, there is a few option of PET radiopharmaceuticals for diagnosis of ischemic heart diseases. Thus, three kinds of 18F-labeled phosphonium cation derivatives, [18F]fluoroalkylphosphonium salts ([18F]FATPs) were synthesized which were accumulated in myocardium. Here, we compared and analyzed the first-pass extraction fraction value (EF) and microPET images of each [18F]FATP with [13N]NH3. Methods The EF of the [18F]FATPs ([18F]FPTP, [18F]FHTP, [18F]FETP) and [13N]NH3 were measured in isolated rat hearts perfused with the Langendorff method (flow velocities: 0.5, 4.0, 8.0, 16.0 ml/min, n &gt;6, each compound and each velocity). Normal rats were imaged with microPET for 30 min after i.v. injection of 37 MBq of [18F]FATPs and [13N]NH3. Results The EF of [18F]FATPs was over 30% at 0.5 ml/min respectively and [18F]FATPs showed higher EF than [13N]NH3 in 4.0, 8.0, 16.0 ml/min (Table 1). The heart-to-lung, heart-to-liver ratios of [18F]FPTP, [18F]FHTP, [18F]FETP, [13N]NH3 were 5.47 ± 0.54, 6.41 ± 0.58, 6.01 ± 0.82, 2.08 ± 0.49 and 2.53 ± 0.31, 3.85 ± 0.11, 3.03 ± 0.76, 0.62 ± 0.04 respectively at 10 min after injection indicating that [18F]FATPs are optimal cardiac imaging agents. Conclusions [18F]FATPs showed higher EF, more stable uptake in the myocardium and more rapid clearance from liver or lung than [13N]NH3, that could lead to excellent image quality. [18F]FATPs might have a potential to be utilized as a novel myocardial agent for cardiac PET/CT applications.